Qiagen N.V. (QGEN) SEC Filings & Earnings Calls
EquiReason read 13 Qiagen N.V. SEC filings in the last 12 months. Latest: 6-K on 2026-10-23 — Qiagen N.V. announced a planned tender offer by Crown NL Bidco B.V. to acquire all outstanding shares at €46.50 per share, pursuant to a Business Combination Agreement dated Octobe.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 10.9B
- Annual P/E
- —
- Dividend yield
- 0.5%
- 52-week
- —
- Next earnings
- 2 Feb, in 101 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
23 Oct 20266-KQiagen N.V. announced a planned tender offer by Crown NL Bidco B.V. to acquire all outstanding shares at €46.50 per share, pursuant to a Business Combination Agreement dated October 21, 2026.open
Risks flagged
Transaction completion risk due to regulatory approvals, shareholder tenders, and potential competing offers
“risks relating to: the proposed transaction not being timely completed, if completed at all; uncertainties as to the number of QIAGEN ordinary shares that will be tendered; the possibility that competing offers will be made; regulatory approvals required for the transaction not being timely obtained”
9 Sep 20266-KQiagen N.V. announced the appointment of Jonathan M. Pratt as CEO effective September 1, 2026, succeeding Thierry Bernard. The company reaffirmed its Q3 and full-year 2026 outlook; strategic review continues.open
Guidance
Qiagen reaffirmed Q3 and full-year 2026 outlook; no specific numbers provided in excerpt.
Risks flagged
CEO transition risk; new leader may shift strategy or execution.
“CEO change introduces uncertainty; Thierry Bernard stepping down, transition through year-end.”
Strategic review outcome uncertain; could lead to major changes including sale or restructuring.
“Strategic review ongoing; potential for significant corporate action.”
7 Aug 20266-KQiagen Q2 2026 net sales $535M unchanged YoY, exceeding outlook for ~2% CER decline; adjusted EPS $0.62 above $0.60 guidance; reaffirms FY2026 outlook.open
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $535M | 0% y/y |
| Adjusted diluted EPS · Q2-2026 | $0.62 | |
| Diluted EPS · Q2-2026 | $0.50 | |
| Adjusted operating income margin · Q2-2026 | 29.4% | |
| Operating cash flow · H1-2026 | $301M |
Guidance
Net sales growth ~1-2% CER, adjusted diluted EPS at least $2.43 CER
Reaffirmed FY2026 outlook for ~1-2% CER net sales growth and adjusted EPS >=$2.43 CER
Risks flagged
U.S. immigration testing demand decline and instrument spending pressure
“QuantiFERON sales rise slightly amid lower U.S. immigration testing demand; continued pressure on instrument spending in the U.S.”
7 Aug 20266-KQiagen Q2 2026 net sales $535M unchanged YoY, exceeding outlook for ~2% CER decline; adjusted EPS $0.62 above $0.60 guidance; reaffirms FY2026 outlook.open
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $535M | 0% y/y |
| Adjusted diluted EPS · Q2-2026 | $0.62 | |
| Diluted EPS · Q2-2026 | $0.50 | |
| Adjusted operating income margin · Q2-2026 | 29.4% | |
| Operating cash flow · H1-2026 | $301M |
Guidance
Net sales growth ~1-2% CER, adjusted diluted EPS at least $2.43 CER
Reaffirmed FY2026 outlook for ~1-2% CER net sales growth and adjusted EPS >=$2.43 CER
Risks flagged
U.S. immigration testing demand decline and instrument spending pressure
“QuantiFERON sales rise slightly amid lower U.S. immigration testing demand; continued pressure on instrument spending in the U.S.” · word for word
8 May 20266-KQiagen cut FY2026 net sales growth outlook from at least 5% CER to about 1-2% CER, citing lower QuantiFERON immigration testing demand and cautious U.S. Life Sciences customer demand. Q1 2026 CER sales declined 1% vs. prior outlook for at lopen
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $492M | +2% y/y |
| Adjusted diluted EPS · Q1-2026 | $0.54 | |
| Adjusted operating income margin · Q1-2026 | 27.4% |
Guidance
Net sales growth cut to about 1-2% CER from at least 5%
Full-year 2026 net sales growth guidance cut from at least 5% CER to about 1-2% CER due to lower QuantiFERON and cautious US demand
Risks flagged
Immigration testing demand decline impacting QuantiFERON sales
“QuantiFERON sales affected by significantly lower immigration testing demand” · word for word
Cautious US Life Sciences customer demand
“cautious U.S. Life Sciences customer demand” · word for word
8 May 20266-KQiagen Q1 2026 net sales $492.3M vs $483.5M YoY, net income $68.0M vs $90.8M YoY, but operating income $84.4M vs $115.3M YoY; restructuring costs $32.2M impacted. Revenue up 1.8% YoY, but net income down 25%. Mixed signals.open
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $492M | +2% y/y |
| Diluted EPS · Q1-2026 | $0.33 | -20% y/y |
| Adjusted diluted EPS · Q1-2026 | $0.54 | |
| Adjusted operating income margin · Q1-2026 | 27.4% |
Guidance
Net sales growth cut to about 1-2% CER from at least 5%
Full-year 2026 net sales growth guidance cut from at least 5% CER to about 1-2% CER due to lower QuantiFERON and cautious US demand
Risks flagged
Immigration testing demand decline impacting QuantiFERON sales
“QuantiFERON sales affected by significantly lower immigration testing demand”
Cautious US Life Sciences customer demand
“cautious U.S. Life Sciences customer demand”
1 May 20266-KQIAGEN cut FY2026 net sales growth outlook from at least 5% CER to about 1-2% CER and adjusted EPS from at least $2.50 to at least $2.43 CER, citing lower QuantiFERON immigration testing demand and cautious U.S. Life Sciences spending.open
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $492M | +2% y/y |
| Adjusted diluted EPS · Q1-2026 | $0.54 | |
| Sample technologies sales · Sample technologies · Q1-2026 | $170M | +13% y/y |
| Diagnostic solutions sales · Diagnostic solutions · Q1-2026 | $185M | -1% y/y |
| QuantiFERON sales · QuantiFERON · Q1-2026 | $113M | -3% y/y |
| QIAstat-Dx sales · QIAstat-Dx · Q1-2026 | $36M | +4% y/y |
| PCR/Nucleic acid amplification sales · PCR/Nucleic acid amplification · Q1-2026 | $69M | -9% y/y |
| Genomics/NGS sales · Genomics/NGS · Q1-2026 | $57M | +6% y/y |
| Full-year 2026 adjusted diluted EPS outlook · FY2026 | $2.43 | |
| Q2 2026 adjusted diluted EPS outlook · Q2-2026 | $0.60 | 0% y/y |
Guidance
FY2026 net sales growth cut from at least 5% CER to about 1-2% CER; adjusted EPS cut from at least $2.50 to at least $2.43
Guidance cut reflects significant headwinds from QuantiFERON immigration testing decline and cautious U.S. Life Sciences demand, partially offset by growth pillars and cost discipline.
Risks flagged
QuantiFERON immigration testing demand decline is a significant headwind, expected to persist through 2026
“QuantiFERON sales declined 5% CER from Q1 2025, mainly due to a significant decline in immigration testing demand in the United States and the Middle East.” · word for word
U.S. Life Sciences customer caution and geopolitical uncertainty create demand risk
“sustained caution among U.S. Life Sciences customers and increased geopolitical uncertainty.” · word for word
Tariff and currency headwinds impacting profitability
“headwinds from tariffs, currency movements and measures to ensure reliable product supply” · word for word
20 Mar 202620-FAnnual report filed with no material event;open
Risks flagged
Reimbursement pressure from PAMA
“This calculation methodology has resulted in significant reductions in reimbursement, even though CMS imposed caps on those reductions.” · word for word
6 Feb 20266-KQiagen Q4 2025 net sales $540M (+1% CER) exceeded outlook for steady results; adj. EPS $0.62 CER beat ~$0.60 guidance. FY2025 sales at high end of 4-5% CER growth outlook, adj. EPS $2.40 CER ahead of ~$2.38 guidance. 2026 outlook: at leastopen
Figures in the filing · each found in the filing text
| Net sales · Q4-2025 | $540M | +4% y/y |
| Net sales · FY2025 | $2.09B | +6% y/y |
| Diluted EPS · Q4-2025 | $0.49 | |
| Adjusted diluted EPS · Q4-2025 | $0.62 | |
| Adjusted diluted EPS · FY2025 | $2.40 | |
| Diluted EPS · FY2025 | $1.94 | |
| Adjusted operating income margin · FY2025 | 29.5% | |
| Growth pillars sales · FY2025 | $1.49B | +8% y/y |
| Growth pillars sales guidance · FY2026 | $1.64B | |
| Adjusted diluted EPS guidance · FY2026 | $2.50 |
Guidance
FY2026 net sales growth at least 5% CER, adj. diluted EPS at least $2.50 CER (vs. $2.38 in FY2025).
FY2026 guidance raised: at least 5% CER sales growth, adj. diluted EPS at least $2.50 CER, growth pillars expected to contribute ~$1.64B CER (+9% CER).
Risks flagged
Macroeconomic challenges and U.S. government shutdown impact
“overcoming macroeconomic challenges and the impact of the 2025 U.S. government shutdown” · word for word
Discontinued product headwinds (NeuMoDx and Dialunox)
“Net sales results included headwinds of approximately $10 million from discontinued products (NeuMoDx and Dialunox)” · word for word
Tariff and currency headwinds
“despite tariffs and currency headwinds” · word for word
22 Dec 20256-KQIAGEN announces synthetic share repurchase of up to ~$500M via reverse stock split and capital repayment, reducing shares by ~5%.share dilutionopen
Figures in the filing · each found in the filing text
| Capital Return Amount · 2026-01-07 | $500M | |
| Share Reduction Percentage · 2026-01-07 | 5.0% | |
| Capital Repayment Per Share · 2026-01-07 | $2.29 | |
| Shares Outstanding (Pre) · 2025-12-18 | 217,700,000 |
6 Nov 20256-KQIAGEN exceeds Q3 2025 outlook, raises FY 2025 adjusted EPS target to ~$2.38 CER, announces Parse acquisition and $500M share repurchase; CEO transition plan.open
Figures in the filing · each found in the filing text
| Net sales · Q3-2025 | $533M | +6% y/y |
| Diluted EPS · Q3-2025 | $0.60 | |
| Adjusted diluted EPS · Q3-2025 | $0.61 | |
| Adjusted operating income margin · Q3-2025 | 29.6% | |
| Operating cash flow · Q3-2025 | $165M | |
| Adjusted diluted EPS guidance · FY2025 | $2.38 |
Guidance
FY2025 adj. diluted EPS target raised to ~$2.38 CER (from ~$2.35 CER)
FY2025 outlook reaffirmed for net sales growth of about 4-5% CER; adj. diluted EPS target raised to ~$2.38 CER; margin guidance ~29.5% absorbing currency and tariff headwinds.
Risks flagged
CEO transition risk with Thierry Bernard stepping down after successor appointed
“After six years as CEO, Supervisory Board and Thierry Bernard agree on timing for transition, and for Thierry Bernard to step down after successor is appointed.” · word for word
Currency and tariff headwinds impacting margin guidance
“QIAGEN also expects an adjusted operating income margin of about 29.5% (about 30% CER) in 2025 while absorbing headwinds from currency movements and tariffs.” · word for word
6 Nov 20256-KQIAGEN N.V. reported Q3 2025 net sales of $532.6M (+6.1% YoY), net income of $130M (+32.6% YoY), and diluted EPS of $0.60 (+36.4% YoY), with strong operational performance.open
Figures in the filing · each found in the filing text
| Net sales · Q3-2025 | $533M | |
| Net income · Q3-2025 | $130M | |
| Diluted EPS · Q3-2025 | $0.60 | |
| Cash and cash equivalents · Q3-2025 | $1.36B | |
| Total assets · Q3-2025 | $6.55B |
Qiagen N.V. — questions
- What did Qiagen N.V. file recently?
- 13 SEC filings in the last 12 months. Latest: 6-K on 2026-10-23 — Qiagen N.V. announced a planned tender offer by Crown NL Bidco B.V. to acquire all outstanding shares at €46.50 per share, pursuant to a Business Combination Agreement dated October 21, 2026.
Every figure on this page comes from Qiagen N.V.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.